Compare JPMorgan Nasdaq Equity Premium Income ETF (JEPQ) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Nasdaq Equity Premium Income ETF vs Regeneron Pharmaceuticals Inc — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.89, while Regeneron Pharmaceuticals Inc trades at $794.9 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.47% dividend while JPMorgan Nasdaq Equity Premium Income ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, JPMorgan Nasdaq Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| JEPQ | REGN | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $812.27 |
52-Week Low | $53.77 | $555.51 |
Market Cap | — | $82.06B |
Enterprise Value | — | $76.77B |
Dividend Yield | — | 0.47% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Nasdaq Equity Premium Income ETF
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
